No Clinically Significant Drug Interaction Between Acetyl-L-Carnitine and Apixaban
Acetyl-L-carnitine (Precision Alcar) does not have a clinically significant drug interaction with apixaban and can be safely co-administered.
Pharmacological Basis
The FDA prescribing information for apixaban clearly defines its drug interaction profile 1. Apixaban is metabolized primarily via CYP3A4 (with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2) and is a substrate of P-glycoprotein (P-gp) transport proteins 1.
Clinically significant interactions with apixaban occur only with:
- Combined P-gp AND strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) 1
- Combined P-gp AND strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) 1
Why Acetyl-L-Carnitine Does Not Interact
Acetyl-L-carnitine is an endogenous water-soluble molecule involved in mitochondrial fatty acid transport and energy metabolism 2, 3. It does not:
- Inhibit or induce CYP3A4 enzymes
- Affect P-glycoprotein transport
- Alter hepatic drug metabolism pathways relevant to apixaban
The available research on acetyl-L-carnitine demonstrates its effects on cellular metabolism, mitochondrial function, and ATP synthesis 4, but shows no evidence of cytochrome P450 enzyme interactions or effects on drug transport proteins.
Clinical Evidence
Multiple studies have examined acetyl-L-carnitine's pharmacological effects without identifying drug-drug interactions through CYP450 or P-gp pathways 5, 6, 4, 7, 3. One study specifically examined acetyl-L-carnitine with verapamil (a known P-gp inhibitor) and found that acetyl-L-carnitine's protective effects were mediated through ATP synthase, not through drug metabolism pathways 4.
Practical Recommendation
Continue both medications without dose adjustment. No monitoring beyond standard anticoagulation surveillance is required. The absence of this interaction in FDA labeling 1 and European guidelines 8 that extensively catalog apixaban interactions further supports the safety of this combination.
Important Caveat
While acetyl-L-carnitine does not interact with apixaban pharmacologically, always monitor for bleeding complications when patients are on any anticoagulant, particularly if they have additional bleeding risk factors (age ≥80 years, weight ≤60 kg, renal impairment with creatinine ≥1.5 mg/dL) 9, 1.